← Leaderboards
Roger D Spealman
Harvard University (Medical School)
$14,290,245
Attributed
$16,951,015
Total exposure
50
Grants
26
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–19$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$16,951,015 · 50
By mechanism
R01$14,525,082 · 7
P51$1,014,655 · 40
U42$592,204 · 1
R21$459,000 · 1
T32$360,074 · 1
Top collaborators
- Jack Bergman11 shared
- Brian D. Kangas1 shared
- Stephen John Kohut1 shared
Most similar at Harvard University (Medical School)
Same institution · by research overlap
- James K Rowlett$18,405,189
- David A. Sinclair$25,944,681
- Azad Bonni$17,123,228
- Sam W Lee$15,278,254
- Philip W Hinds$12,088,422
Others in their field
Top investigators on “Cocaine”
- Sten H Vermund · University Of Alabama At Birmingham$115,253,143
- Fred M Gordin · Social And Scientific Systems, Inc.$44,160,542
- Eric J Nestler · Icahn School Of Medicine At Mount Sinai$42,690,128
- Joel Gelernter · Washington University$34,364,949
- Michael A Nader · Emory University$33,226,167
- Shenghan Lai · University Of Miami Coral Gables$31,568,530
Research focus
CocainePharmaceutical PreparationsAgonistBehavioral /Social Science Research TagBaseGrantPrimatesSelf AdministrationRelapseNonhuman PrimateBehaviorStimulusBehavioralDrug AddictionMonkeysResponseFoodFundingSourceUnited States National Institutes Of HealthResearch PersonnelResourcesInstitutionComputer Retrieval Of Information On Scientific Projects Database
Grant awards (86)
Neural, Cognitive and Abuse-Related Consequences of Chronic THC Exposure during Adolescence in Nonhuman Primates$601,606
R01 · FY2019 · DA
Pharmacologic Approaches to Prescription Opioid Addiction and Relapse Prevention$445,211
R01 · FY2018 · DA
Pharmacologic Approaches to Prescription Opioid Addiction and Relapse Prevention$443,481
R01 · FY2017 · DA
Pharmacologic Approaches to Prescription Opioid Addiction and Relapse Prevention$429,512
R01 · FY2016 · DA
Alpha Adrenergic Pharmacotherapy for Polydrug (Stimulant/Opiate) Abuse$423,362
R01 · FY2016 · DA
Pharmacologic Approaches to Prescription Opioid Addiction and Relapse Prevention$473,885
R01 · FY2015 · DA
Alpha Adrenergic Pharmacotherapy for Polydrug (Stimulant/Opiate) Abuse$417,078
R01 · FY2015 · DA
The NEPRC SPF Rhesus Macaque Breeding Colony$592,204
U42 · FY2014 · OD · contact PI
Pharmacologic Approaches to Prescription Opioid Addiction and Relapse Prevention$528,330
R01 · FY2014 · DA
Research Training in Veterinary & Comparative Pathology$101,905
T32 · FY2014 · OD · contact PI
Alpha Adrenergic Pharmacotherapy for Polydrug (Stimulant/Opiate) Abuse$402,588
R01 · FY2013 · DA
Research Training in Veterinary & Comparative Pathology$258,169
T32 · FY2013 · OD · contact PI
Alpha Adrenergic Pharmacotherapy for Polydrug (Stimulant/Opiate) Abuse$415,374
R01 · FY2012 · DA
Alpha Adrenergic Pharmacotherapy for Polydrug (Stimulant/Opiate) Abuse$440,311
R01 · FY2011 · DA
Nonhuman Primate Models of Reinstated Cocaine Seeking$367,379
R01 · FY2011 · DA · contact PI
DOPAMINE D3 RECEPTOR LIGANDS FOR TREATMENT OF SUBSTANCE ABUSE$13,753
P51 · FY2011 · RR · contact PI
Nonhuman Primate Models of Reinstated Cocaine Seeking$378,742
R01 · FY2010 · DA · contact PI
DOPAMINE D3 RECEPTOR LIGANDS FOR TREATMENT OF SUBSTANCE ABUSE$18,052
P51 · FY2010 · RR · contact PI
ASYMMETRICAL COCAINE-OPIOID INTERACTIONS$18,052
P51 · FY2010 · RR · contact PI
STRATEGIES FOR AUGMENTING EXTINCTION OF DRUG SEEKING$18,052
P51 · FY2010 · RR · contact PI
KAPPA OPIOIDS AND RELAPSE TO DRUG SEEKING$18,052
P51 · FY2010 · RR · contact PI
NOVEL THERAPEUTIC APPROACHES FOR PARKINSON'S DISEASE$18,052
P51 · FY2010 · RR · contact PI
Nonhuman Primate Models of Reinstated Cocaine Seeking$382,568
R01 · FY2009 · DA · contact PI
PHARMACOLOGICAL STRATEGIES FOR AUGMENTING EXTINCTION OF DRUG SEEKING$12,721
P51 · FY2009 · RR · contact PI
MONOAMINERGIC MECHANISMS UNDERLYING RELAPSE TO COCAINE ADDICTION$12,721
P51 · FY2009 · RR · contact PI
DOPAMINE D3 RECEPTOR LIGANDS FOR TREATMENT OF SUBSTANCE ABUSE$12,721
P51 · FY2009 · RR · contact PI
ROLE OF MU AGONIST EFFICACY IN OPIOID ENHANCEMENT OF COCAINE SELF-ADMINISTRATION$12,721
P51 · FY2009 · RR · contact PI
KAPPA OPIOIDS AND RELAPSE TO DRUG SEEKING$12,721
P51 · FY2009 · RR · contact PI
Nonhuman Primate Models of Reinstated Cocaine Seeking$382,568
R01 · FY2008 · DA · contact PI
mGluR5 Mechanisms in Primate Models of Cocaine Abuse$353,335
R01 · FY2008 · DA · contact PI
PHARMACOLOGICAL STRATEGIES FOR AUGMENTING EXTINCTION OF DRUG SEEKING$10,814
P51 · FY2008 · RR · contact PI
DOPAMINE D3 RECEPTOR LIGANDS FOR TREATMENT OF SUBSTANCE ABUSE$10,814
P51 · FY2008 · RR · contact PI
MECHANISMS AND TREATMENT OF SPEEDBALL ABUSE$10,814
P51 · FY2008 · RR · contact PI
KAPPA OPIOIDS AND RELAPSE TO DRUG SEEKING$10,814
P51 · FY2008 · RR · contact PI
Nonhuman Primate Models of Reinstated Cocaine Seeking$390,375
R01 · FY2007 · DA · contact PI
mGluR5 Mechanisms in Primate Models of Cocaine Abuse$360,546
R01 · FY2007 · DA · contact PI
Nonhuman Primate Models of Speedball Abuse$320,485
R01 · FY2007 · DA · contact PI
mGluR5 Mechanisms in Primate Models of Cocaine Abuse$371,315
R01 · FY2006 · DA · contact PI
Nonhuman Primate Models of Speedball Abuse$330,057
R01 · FY2006 · DA · contact PI
CONTRIBUTION OF GABA-A RECEPTOR SUBTYPES TO THE SUBJECTIVE EFFECTS OF ETHANOL$27,966
P51 · FY2006 · RR · contact PI
KAPPA OPIOIDS INDUCE REINSTATEMENT OF COCAINE-SEEKING VIA NON-OPIOID MECHANISMS$27,966
P51 · FY2006 · RR · contact PI
ETONITAZENE ENHANCED COCAINE SELF-ADMINISTRATION IS NOT BLOCKED BY NALOXONAZINE$27,966
P51 · FY2006 · RR · contact PI
METABOTROPIC GLUTAMATE RECEPTORS IN COCAINE ABUSE AND RELAPSE$27,966
P51 · FY2006 · RR · contact PI
SUBJECTIVE EFFECTS OF COCAINE AND HEROIN: OPIOID RECEPTOR MECHANISMS$27,966
P51 · FY2006 · RR · contact PI
ROLE OF OPIOID RECEPTOR SUBTYPES IN THE SUBJECTIVE EFFECTS OF ETHANOL$27,966
P51 · FY2006 · RR · contact PI
Nonhuman Primate Model of Cocaine Relapse and Treatment$382,500
R01 · FY2005 · DA
mGluR5 Mechanisms in Primate Models of Cocaine Abuse$380,250
R01 · FY2005 · DA
Nonhuman Primate Models of Speedball Abuse$338,000
R01 · FY2005 · DA
GABA A/alpha5 Ligands in Primate Models of Alcohol Abuse$153,000
R21 · FY2005 · AA
MODULATION OF SUBJECTIVE AND REINFORCING EFFECTS OF COCAINE BY ETONITAZENE$12,825
P51 · FY2005 · RR
Nonhuman Primate Model of Cocaine Relapse and Treatment$382,500
R01 · FY2004 · DA
mGluR5 Mechanisms in Primate Models of Cocaine Abuse$380,250
R01 · FY2004 · DA
Nonhuman Primate Models of Speedball Abuse$338,000
R01 · FY2004 · DA
GABA A/alpha5 Ligands in Primate Models of Alcohol Abuse$153,000
R21 · FY2004 · AA
OPIOID PARTIAL AGONIST EFFECTS OF 3-O-METHYLNALTREXONE$11,895
P51 · FY2004 · RR
SALIVARY CORTISOL SAMPLE IN UNRESTRAINED SQUIRREL MONKEY$11,895
P51 · FY2004 · RR
ATTENUATION OF COCAINE AND FOOD SELF-ADMINISTRATION$11,895
P51 · FY2004 · RR
SECOND-ORDER SCHEDULE OF COCAINE SELF-ADMINISTRATION$11,895
P51 · FY2004 · RR
KAPPA AGONIST MODULATION OF COCAINE PRIMING-INDUCED$11,895
P51 · FY2004 · RR
GABA-A RECEPTOR MECHANISMS IN THE SUBJECTIVE EFFECTS$11,895
P51 · FY2004 · RR
BLOCKADE OF ALPHA2-ADRENOCEPTORS INDUCES REINSTATEMENT$11,895
P51 · FY2004 · RR
SUPPRESSION OF COCAINE-MAINTAINED BEHAVIOR BY D2R LIGAND$11,895
P51 · FY2004 · RR
Nonhuman Primate Model of Cocaine Relapse and Treatment$382,500
R01 · FY2003 · DA
Nonhuman Primate Models of Speedball Abuse$338,000
R01 · FY2003 · DA
BEHAVIOR CONTROLLED BY DRUG INJECTIONS$336,785
R01 · FY2003 · DA
GABA A/alpha5 Ligands in Primate Models of Alcohol Abuse$153,000
R21 · FY2003 · AA
ACTIVATION OF HPA AXIS DOES NOT REINSTATE COCAINE-SEEKING BEHAVIOR$10,444
P51 · FY2003 · RR
REINSTATEMENT OF COCAINE-SEEKING BY YOHIMBINE AND REVERSAL BY CLONIDINE$10,444
P51 · FY2003 · RR
ATTENUATION OF COCAINE'S DISCRIMINATIVE STIMULUS EFFECTS BY AN MGLUR5 ANTAGONIST$10,444
P51 · FY2003 · RR
ROLE OF METABOTROPIC GLUTAMATE TYPE 5 RECEPTORS IN COCAINE-SEEKING BEHAVIOR$10,444
P51 · FY2003 · RR
OPPOSITE MODULATION OF COCAINE SEEKING BY MU- AND KAPPA-OPIOID AGONISTS$10,444
P51 · FY2003 · RR
OPPOSITE MODULATION OF HEROIN SELF-ADMINISTRATION BY DOPAMINE D1 AND D2 AGONISTS$10,444
P51 · FY2003 · RR
EVALUATION OF NEW METHYLPYENIDATES$10,444
P51 · FY2003 · RR
ASYMMETRIC INTERACTIONS BETWEEN THE SUBJECTIVE EFFECTS OF COCAINE AND HEROIN$10,444
P51 · FY2003 · RR
Nonhuman Primate Model of Cocaine Relapse and Treatment$382,500
R01 · FY2002 · DA
BEHAVIOR CONTROLLED BY DRUG INJECTIONS$326,982
R01 · FY2002 · DA
ANIMAL MODEL OF SPEEDBALL ABUSE--MECHANISMS &TREATMENT$299,854
R01 · FY2002 · DA
PHARMACOLOGICAL REPLACEMENT STRATEGIES FOR STIMULANT ADDICTION$111,112
P51 · FY2002 · RR
NOVEL H3 ANTAGONISTS FOR ADHD ABUSE POTENTIAL$111,112
P51 · FY2002 · RR
Nonhuman Primate Model of Cocaine Relapse and Treatment$382,500
R01 · FY2001 · DA
BEHAVIOR CONTROLLED BY DRUG INJECTIONS$326,025
R01 · FY2001 · DA
ANIMAL MODEL OF SPEEDBALL ABUSE--MECHANISMS &TREATMENT$291,122
R01 · FY2001 · DA
NOVEL H3 ANTAGONISTS FOR ADHD ABUSE POTENTIAL$111,112
P51 · FY2001 · RR
PHARMACOLOGICAL REPLACEMENT STRATEGIES FOR STIMULANT ADDICTION$111,112
P51 · FY2001 · RR
BEHAVIOR CONTROLLED BY DRUG INJECTIONS$316,563
R01 · FY2000 · DA
ANIMAL MODEL OF SPEEDBALL ABUSE--MECHANISMS &TREATMENT$282,643
R01 · FY2000 · DA